Campbell & CO Investment Adviser LLC
Position in ARWR — Arrowhead Pharmaceuticals, Inc.
CIK 1353570
BALTIMORE, MD
Position in ARWR
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,187,287
+$826,967 QoQ
Shares Held
18,936
-1.2% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ARWR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Campbell & CO Investment Adviser LLC holds $72,173,828 across 47 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
9,899 | $6,172,422 | |
| 2 | CRSP |
CRISPR Therapeutics AG
|
107,529 | $5,864,631 | |
| 3 | CYTK |
Cytokinetics Inc
|
65,978 | $5,620,665 | |
| 4 | INSM |
INSMED Inc
|
43,856 | $4,675,926 | |
| 5 | IONS |
Ionis Pharmaceuticals Inc
|
49,632 | $3,935,321 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
44,702 | $3,498,825 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
11,183 | $3,366,418 | |
| 8 | RPRX |
Royalty Pharma plc
|
52,688 | $2,954,216 |
All Filings in ARWR
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,187,287 | 18,936 | Shares | Sole | 2026-05-15 | |
| 2024-12-31 | $360,320 | 19,166 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $2,784,573 | 143,757 | Shares | Sole | 2024-11-12 | |
| 2024-03-31 | $1,081,537 | 37,816 | Shares | Sole | 2024-05-10 | |
| 2023-12-31 | $488,406 | 15,961 | Shares | Sole | 2024-02-13 | |
| 2022-06-30 | $319,882 | 9,085 | Shares | Sole | 2022-08-09 | |
| No filing history on record for this holder in this stock. | ||||||